This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rudmann, D. G. Articles by Durham, S. K. Search for Related Content PubMed PubMed Citation Articles by Rudmann, D. G. Articles by Durham, S. K. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Utilization of Genetically Altered Animals in the Pharmaceutical Industry

Department of Pathology, DuPont Pharmaceuticals Company, Newark, Delaware 19714, daniel.g.rudmann.2 @ dupontpharma.com.

Stephen K. Durham

Department of Experimental Pathology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543

The study of transgenic and gene-deleted (knockout) mice provides important insights into the in vivo function and interaction of specific gene products. Within the pharmaceutical industry, genetically altered mice are used predominantly in discovery research to characterize the diverse functions of one or multiple gene products or to establish animal models of human disease for proof-of-concept studies. We recently used genetically altered animals in drug discovery to examine the NF-KB family of transcriptional regulatory genes and to elucidate their essential role in the early onset of immune and inflammatory responses. Transgenic and knockout mice are also useful in drug development, because questions regarding risk assessment and carcinogenesis, xenobiotic metabolism, receptor- and ligand-mediated toxicity, and immunotoxicity can be evaluated using these genetically altered mice. For example, the p53 knockout mouse is one of several genetically altered mice whose use may increase the sensitivity and decrease the time and cost of rodent carcinogenicity bioassays. As with any experimental model system, data obtained from genetically altered mice must be interpreted carefully. The complete inactivation of a gene may result in altered expression of related genes or physiologic compensation for the loss of the gene product. Consideration must also be given to the genetic background of the mouse strain and the impact of strain variability on disease or toxicity models. Despite these potential limitations, knockout mice provide a powerful tool for the advancement of drugs in the pharmaceutical industry.

Key Words: Pharmaceuticals • risk assessment • drug discovery • transgenics • knockout mice • review

References

• Askew GR, Doetschman T., and Lingrel JB (1993). Site-directed point mutations in embryonic stem cells: A gene-targeting tag-and-exchange strategy. Mol. Cell. Biol. 13: 4115-4124.[Abstract/Free Full Text]
• Atrip JH, Itescu S., Minanov OP, Kwiatkowski PA, and Michler PE (1997). Cardiac xenotransplantation. Curr. Opin. Cardiol. 12: 172-178.[Web of Science][Medline] [Order article via Infotrieve]
• Attar RM, Caamano J., Carrasco D., Iotsova V., Ishikawa H., Ryseck RP, Weih F., and Bravo R. (1997). Genetic approaches to study Rel/ NF-kB/IkB function in mice. Cancer Biol. 8: 93-101.[CrossRef]
• Barinaga M. (1994). Knockout mice: Round two [news; comment]. Science 265: 26-28. [Published erratum appears in Science 265: 855.][Abstract/Free Full Text]
• Bedell MA, Jenkins NA, and Copeland NG (1996). Good genes in bad neighborhoods. Nat. Genet. 12: 229-232.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Beg AA, Sha WC, Bronson RT, Ghosh S., and Baltimore D. (1995). Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-KB. Nature 376: 167-169.[CrossRef][Medline] [Order article via Infotrieve]
• Braselmann S., Graninger P., and Busslinger M. (1993). A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins. Proc. Natl. Acad. Sci. USA 90: 1657-1661.[Abstract/Free Full Text]
• Capecchi MR (1989). The new mouse genetics: Altering the genome by gene targeting. Trends Genet. 5: 70-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Charreau B., Tesson L., Soulillou JP, Pourcel C., and Anegon I. (1996). Transgenesis in rats: Technical aspects and models. Transgenic Res. 5: 223-234.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Contrera JF and DeGeorge JJ (1998). In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals. Environ. Health Perspect. 106(suppl. 1): 71-80.[Web of Science][Medline] [Order article via Infotrieve]
• Copp AJ (1995). Death before birth: Clues from gene knockouts and mutations. Trends Genet. 11: 87-93.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cuthbertson RA and Klintworth GK (1988). Transgenic mice—A gold mine for furthering knowledge in pathobiology. Lab. Invest. 58: 484-502.[Web of Science][Medline] [Order article via Infotrieve]
• de Vries A., van Oostrom Ctm, Hofhuis Fma, Dortant PM, Berg Rjw, de Gruijl FR, Wester PW, van Kreijl CF, Capel Pja, van Steeg H., and Verbeek SJ (1995). Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 377: 169-173.[CrossRef][Medline] [Order article via Infotrieve]
• Donehower LA, Harvey M., Slagle BL, McArthur MJ, Montogomery CA, Butel JS, and Bradley A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.[CrossRef][Medline] [Order article via Infotrieve]
• Eastin WC (1998). The U.S. National Toxicology Program evaluation of transgenic mice as predictive models for identifying carcinogens. Environ. Health Perspect. 106(suppl. 1): 81-84.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Evans MJ and Kaufman MH (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature 292: 154-156.[CrossRef][Medline] [Order article via Infotrieve]
• Feil R., Brocard J., Mascrez B., LeMeur M., Metzger D., and Chambon P. (1996). Ligand-activated site-specific recombination in mice. Proc. Natl. Acad. Sci. USA 93: 10887-10890.[Abstract/Free Full Text]
• Fernandez-Salguero P., Pineau T., Hilbert DM, McPhail T., Lee Sst, Kimura S., Nebert DW, Rudikoff S., Ward JM, and Gonzalez FJ (1995). Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 268: 722-726.[Abstract/Free Full Text]
• Frieberg T. and Wolf CR (1996). Recombinant DNA technology as an investigative tool in drug metabolism research. Adv. Drug Deliv. Rev. 22: 187-213.[CrossRef][Web of Science]
• Garrick D., Fiering S., Martin DI, Whitelaw E. (1998). Repeat-induced gene silencing in mammals (see comments). Nat. Genet. 18: 56-59.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gordon JW and Ruddle FH (1981). Integration and stable germ line transmission of genes injected into mouse pronuclei. Science 214: 1244-1246.[Abstract/Free Full Text]
• Gu H., Marth JD, Orban PC, Mossmann H., and Rajewsky K. (1994). Deletion of a DNA polymerase b gene segment in T cells using cell type-specific gene targeting. Science 265: 103-106.[Abstract/Free Full Text]
• Harvey M., McArthur MJ, Montgomery Caj, Bradley A., and Donehower LA (1993). Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 7: 938-943.[Abstract]
• Houdebine LM (1994). Production of pharmaceutical proteins from transgenic animals. J. Biotechnol. 34: 269-287.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Jaenisch R. (1976). Germ line integration and Mendelian transmission of the exogenous Moloney leukemia virus. Proc. Natl. Acad. Sci. USA 73: 1260-1264.[Abstract/Free Full Text]
• Jaenisch R. (1988). Transgenic animals. Science. 240: 1468-1474.[Abstract/Free Full Text]
• Jaenisch R., Fan H., and Kroker B. (1975). Infection of preimplantation mouse embyros and of newborn mice with leukemia virus: Tissue distribution of viral DNA and RNA and leukemogenesis in the adult animal. Proc. Natl. Acad. Sci. USA 72: 4008-4012.[Abstract/Free Full Text]
• Jaenisch R. and Mintz B. (1974). Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. Proc. Natl. Acad. Sci. USA 71: 1250-1254.[Abstract/Free Full Text]
• Kuhn R., Schwenk F., Aguet M., and Rajewsky K. (1995). Inducible gene targeting in mice. Science 269: 1427-1429.[Abstract/Free Full Text]
• Lee Sst, Pineau T., Drago J., Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H., and Gonzalez FJ (1995). Targeted disruption of the isoform of the peroxisome proliferatoractivated receptor gene in mice results in abolishment of the pleiotrophic effects of peroxisome proliferators. Mol. Cell. Biol. 15: 3012-3022.[Abstract]
• Lovik M. (1997). Mutant and transgenic mice in immunotoxicology: An introduction. Toxicology 119: 65-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• MacGregor JT, Farr S., Tucker JD, Heddle JA. Tice RR, and Turteltaub KW (1995). New molecular endpoints and methods in routine toxicity testing. Fundam. Appl. Toxicol. 26: 156-173.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Monro AM and MacDonald JS (1998). Evaluation of the carcinogenic potential of pharmaceuticals. Drug Safety 18: 309-319.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Morrison V. and Ashby J. (1994). A preliminary evaluation of the performance of the Muta Mouse (lacZ) and Big Blue (lacI) transgenic mouse mutation assays. Mutagenesis 9: 367-376.[Abstract/Free Full Text]
• Nebert DW and Duffy JJ (1997). How knockout mouse lines will be used to study the role of drug-metabolizing enzymes and their receptors during reproduction and development, and in environmental toxicity, cancer, and oxidative stress. Biochem. Pharmacol. 53: 249-254.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• No D., Yao TP, and Evans RM (1996). Ecdysome-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. USA 93: 3346-3351.[Abstract/Free Full Text]
• Perez P., Lira SA, and Bravo J. (1995). Overexpression of RelA in transgenic mouse thymocytes: Specific increase on levels of the inhibitor IKBa. Mol. Cell. Biol. 15: 3523-3530.[Abstract]
• Robinson D. (1998). ILSI's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk. Toxicol. Pathol. 26: 474-475.[Free Full Text]
• Rosenberg MP (1997). Gene knockout and transgenic technologies in risk assessment: The next generation. Mol. Carcinog. 20: 262-274.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ryffel B. (1997). Impact of knockout mice in toxicology. Crit. Rev. Toxicol. 27: 135-154.[Web of Science][Medline] [Order article via Infotrieve]
• Sauer B. and Henderson N. (1990). Targeted insertion of exogenous DNA into the eukaryotic genome by the Cre recombinase. New Biol. 2: 441-449.[Medline] [Order article via Infotrieve]
• Shastry BS (1998). Gene disruption in mice: Models of development and disease. Mol. Cell. Biochem. 181: 163-179.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Shockett PE and Schatz DG (1996). Diverse strategies for tetracycline-regulated inducible gene expression. Proc. Natl. Acad. Sci. USA 90: 1657-1661.[CrossRef]
• Sibilia M. and Wagner EF (1995). Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269: 230-234.[Abstract/Free Full Text]
• Spencer DM (1996). Creating conditional mutations in mammals. Trends Genet. 12: 181-187.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• St-Onge L., Furth PA, and Gruss P. (1996). Temporal control of the Cre recombinase in transgenic mice by a tetracycline responsive promoter. Nucleic Acids Res. 19: 3875-3877.
• Tennant RW, French JE, and Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassay using transgenic mouse models. Environ. Health Perspect. 103: 942-950.[Web of Science][Medline] [Order article via Infotrieve]
• Thomas KR and Capecchi MR (1987). Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51: 503-512.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Travis J. (1992). Scoring a technical knockout in mice. Science 256: 1392-1394.[Free Full Text]
• Weih F., Durham SK, Barton DS, Sha WC, Baltimore D., and Bravo R. (1997). p50-NF-B complexes partially compensate for the absence of Rel B: Severely increased pathology in p50-/-relB-/- double-knockout mice. J. Exp. Med. 185: 1-12.[Abstract/Free Full Text]
• Yamamota S., Urano K., Koizumi H., Wakana S., Hioki K., Mitsumori K., Kurokawa Y., Hayashi Y., and Nomura T. (1998). Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenecity testing. Environ. Health Perspect. 106(suppl. 1): 57-69.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 27, No. 1, 111-114 (1999)
DOI: 10.1177/019262339902700121


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Fakhrzadeh, J. D. Laskin, and D. L. Laskin Deficiency in Inducible Nitric Oxide Synthase Protects Mice from Ozone-Induced Lung Inflammation and Tissue Injury Am. J. Respir. Cell Mol. Biol., April 1, 2002; 26(4): 413 - 419. [Abstract] [Full Text] [PDF]

				G. L. Cockerell, J. M. Mckim JR, and S. L. Vonderfecht Strategic Importance of Research Support through Pathology Toxicol Pathol, January 1, 2002; 30(1): 4 - 7. [Abstract] [PDF]

				T. F. Bumol and A. M. Watanabe Genetic Information, Genomic Technologies, and the Future of Drug Discovery JAMA, February 7, 2001; 285(5): 551 - 555. [Abstract] [Full Text] [PDF]

				C.A. SCHMITT, R.R. WALLACE-BRODEUR, C.T. ROSENTHAL, M.E. MCCURRACH, and S.W. LOWE DNA Damage Responses and Chemosensitivity in the E{micro}-myc Mouse Lymphoma Model Cold Spring Harb Symp Quant Biol, January 1, 2000; 65(0): 499 - 510. [Abstract] [PDF]

				B. D. Car and R. T. Robertson Commentary: Discovery Toxicology--A Nascent Science Toxicol Pathol, July 1, 1999; 27(4): 481 - 483. [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rudmann, D. G. Articles by Durham, S. K. Search for Related Content PubMed PubMed Citation Articles by Rudmann, D. G. Articles by Durham, S. K. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?